<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311464</url>
  </required_header>
  <id_info>
    <org_study_id>M16-119</org_study_id>
    <nct_id>NCT03311464</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan</brief_title>
  <official_title>A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab
      in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Anticipated">July 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who have achieved target Pyoderma Gangrenosum Area Reduction (PGAR)</measure>
    <time_frame>Week 26</time_frame>
    <description>The participants will be assessed whether they meet target PGAR at Week 26 based on PGAR score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Physician's Global Assessment (PGA) 0 or 1</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>The Investigator assesses the global improvement of all ulcers including the target ulcer according to the scales at the specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to occurrence of new PG ulcers</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>A new PG ulcer is defined as not present at Baseline and not caused by the epithelial bridging of an existing ulcer at Baseline. The time after Baseline when the new lesion was observed will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total number of active ulcers</measure>
    <time_frame>Week 26</time_frame>
    <description>The number of all active PG ulcers will be counted at the specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>The DLQI will be used to assess the symptoms and the impact of skin problems on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in total ulcer area</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>The change in total ulcer area is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with inflammation reduction as assessed on an Investigator Inflammation Assessment (IIA) Score</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>The Investigator assesses the inflammation status of the target ulcer at the specified visits according to the scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to occurrence of a new PG ulcer(s)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Mean time to occurrence of a new PG ulcer(s) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to healing of target ulcer</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving healing per PGAR for the target ulcer</measure>
    <time_frame>Week 52</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who have achieved target PGAR</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in target Pyoderma Gangrenosum (PG) ulcer area</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>The percentage change in target PG ulcer area is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving PGA 0</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>The Investigator assesses the global improvement of all ulcers including the target ulcer according to the scales at the specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pain as measured by Numerical Rating Scale (NRS)</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>The Numerical Rating Scale of Pain sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the proportion of participants taking analgesics</measure>
    <time_frame>Week 6 and Week 26</time_frame>
    <description>Proportion of participants taking analgesics is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Velocities of healing</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>This is assessed from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving ulcer healing as assessed by PGAR</measure>
    <time_frame>Week 6</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving PGA 0 of all PG ulcers</measure>
    <time_frame>Week 52</time_frame>
    <description>The Investigator assesses the global improvement of all ulcers including the target ulcer according to the scales at the specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to relapse of the target PG ulcer</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to healing as defined by PGAR</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>The PG Area Reduction (PGAR) is calculated as the percentage area change in the target PG ulcer from Baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pyoderma Gangrenosum</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Study drug will be administered subcutaneously.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>HumiraÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be able and willing to provide written informed consent. If the
             participant is &lt; 20 years old, a parent or legal guardian must be willing to give
             written informed consent

          -  Participants must have a diagnosis of ulcerative (classic) PG made by the Investigator

          -  Participants must have demonstrated an inadequate response to conventional PG therapy
             or in the opinion of the Investigator they are not a suitable candidate for
             conventional PG treatment.

        Exclusion Criteria: - Participants with pustular, bullous/atypical, or vegetative variants
        of PG

          -  Participants with clinical evidence of ulceration that is non-PG related, vasculitis,
             thrombosisprone conditions, or monoclonal gammopathy

          -  Participants with a histopathological finding that is consistent with a diagnosis
             other than PG

          -  Participants receiving a therapeutic dose of prednisolone

          -  Participants with prior exposure to adalimumab or previous participation in an
             adalimumab clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie GK Clinical Trial Registration Desk</last_name>
    <phone>+81-3-4577-1111</phone>
    <email>abbvie_jpn_info_clingov@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo Univ Urayasu Hosp</name>
      <address>
        <city>Urayasu Shi</city>
        <state>Chiba</state>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>ã390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>ã852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hosp</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Higashi-ku</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima-shi</city>
        <state>Tokushima</state>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hosp</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>æ¿æ©åº</city>
        <state>Tokyo</state>
        <zip>ã173-8605</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical Univ Hosp</name>
      <address>
        <city>Asahikawa-shi</city>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Med Univ Hosp</name>
      <address>
        <city>Fukushima-shi</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical Univ Hosp</name>
      <address>
        <city>Hirakata-shi, Osaka</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>UBE</city>
        <zip>755-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Showa Univ Fujigaoka Hosp</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>227-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyoderma Gangrenosum</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>HumiraÂ®</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

